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University Campus, University of Ioannina, Ioannina, GreeceA B S T R A C TDespite the great realized or potential value of network meta-analysis
of randomized controlled trial evidence to inform health care decision
making, many decision makers might not be familiar with these
techniques. The Task Force developed a consensus-based 26-item
questionnaire to help decision makers assess the relevance and
credibility of indirect treatment comparisons and network meta-
analysis to help inform health care decision making. The relevance
domain of the questionnaire (4 questions) calls for assessments about
the applicability of network meta-analysis results to the setting of
interest to the decision maker. The remaining 22 questions belong to
an overall credibility domain and pertain to assessments about
whether the network meta-analysis results provide a valid answer
to the question they are designed to answer by examining 1) the used




ndence to: Jeroen Jansen, Redwood Outcomes, Bostransparency, 4) interpretation of ﬁndings, and 5) conﬂicts of interest.
The questionnaire aims to help readers of network meta-analysis
opine about their conﬁdence in the credibility and applicability
of the results of a network meta-analysis, and help make
decision makers aware of the subtleties involved in the analysis of
networks of randomized trial evidence. It is anticipated that user
feedback will permit periodic evaluation and modiﬁcation of the
questionnaire.
Keywords: bias, checklist, credibility, decision making, indirect
comparisons, mixed treatment comparisons, multiple treatment com-
parison, network meta-analysis, questionnaire, relevance, validity.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Four Good Practices task forces developed a consensus-based set of
questionnaires to help decision makers evaluate 1) prospective and
2) retrospective observational studies, 3) network meta-analysis
(indirect treatment comparison), and 4) decision analytic modeling
studies with greater uniformity and transparency [1,2]. The primary
audiences of these questionnaires are assessors and reviewers of
health care research studies for health technology assessment,
drug formulary, and health care services decisions requiring vary-
ing levels of knowledge and expertise. This report focuses on the
questionnaire to assess the relevance and credibility of network
meta-analysis (including indirect treatment comparison).
Systematic reviews of randomized controlled trials (RCTs) are
considered a key summary of evidence for informing clinical
practice guidelines, formulary management, and reimbursement
policies. Many systematic reviews use meta-analysis to synthesizeevidence from several RCTs addressing the same question [3].
Sound comprehensive decision making requires comparisons of
all relevant competing interventions. Ideally, well-designed and
conducted RCTs would simultaneously compare all interventions
of interest. Such studies are almost never available, thereby
complicating decision making [4–7]. New drugs are often com-
pared with placebo or standard care, but not against each other, in
trials aiming to contribute toward obtaining approval for drug
licensing; there may be no commercial incentive to compare the
new treatment with an active control treatment. Even if there was
an incentive to incorporate competing interventions in an RCT,
the interventions of interest may vary by country or have changed
over time because of new evidence and treatment insights. Finally,
for some indications, the relatively large number of competing
interventions makes a trial incorporating all of them impractical.
In the absence of trials involving a direct comparison of
treatments of interest, an indirect comparison can provide usefulociety for Pharmacoeconomics and Outcomes Research (ISPOR).
ton, MA 02108.
Background to the Task Force
On May 21, 2011, the Board of Directors approved, in principle,
ISPOR’s participation with the Academy of Managed Care
Pharmacy (AMCP) and the National Pharmaceutical Council
(NPC) in the Comparative Effectiveness Research Collaborative
Initiative (CER-CI) for advancing appropriate use of outcomes
research evidence to improve patient health outcomes. ISPOR’s
contribution to the CER-CI was to develop articles on how to
assess prospective and retrospective observational studies,
indirect treatment comparison (network meta-analysis), and
decision analytic modeling studies to inform health care
decision making. Good Practice task forces were created to
develop these articles. Task Force Chairs were identified from
leaders of ISPOR Good Research Practices task forces. Each Task
Force consisted of two members from the AMCP, the NPC, and
the ISPOR.
Each Task Force met independently via teleconference. In
addition, the Task Force Chairs met via teleconferences and
face-to-face meetings held on April 20, 2012 (San Francisco, CA,
USA), June 3, 2012 (Washington, DC, USA), June 28-29, 2012
(Boston, MA, USA), November 4, 2012 (Berlin, Germany), and
May 21, 2013 (New Orleans, LA, USA), to coordinate a common
outline and format for these articles. A focus group representing
the US formulary decision-making community (22 participants)
was convened April 19, 2012, at the AMCP Meeting, San
Francisco, CA, USA, for feedback on the draft outline, format,
and content of the assessment articles. The content of these
reports was presented for comment at the ISPOR Annual
International Meetings held June 10, 2012, and May 22, 2013,
and during the European Congress held November 5 and 6, 2012.
A draft indirect treatment/network meta-analysis Task Force
report was sent for comment to the Task Force review group on
August 5, 2013. Written comments were considered, and a final
draft report was sent for comment to the ISPOR membership on
September 24, 2013. A total of 54 written comments were
received. All written comments are published on the ISPORWeb
site, which can be accessed via the Research menu on ISPOR’s
home page: http://www.ispor.org. The final report was sub-
mitted to Value in Health.
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peting interventions (which otherwise would be lacking) and for
judiciously selecting the best choice(s) of treatment. For example,
we can indirectly compare two treatments, which have never
been compared against each other in an RCT, if each has been
compared against the same comparator [7–14].
Although it is often argued that indirect comparisons are
needed only when direct comparisons are not available, it is
important to realize that to use all available evidence, one should
combine information from both direct and indirect comparisons.
A collection of RCTs informing on several treatments constitutes
a network of evidence, in which each RCT directly compares a
subset, but not necessarily all, of treatments. Such a network
involving treatments compared directly, indirectly, or both can be
synthesized by means of network meta-analysis [10–14]. In tradi-
tional meta-analysis, all included studies compare the same
intervention with the same comparator. Network meta-analysis
extends this concept by including multiple pairwise comparisons
across a range of interventions and provides estimates of relative
treatment effects on multiple treatment comparisons for com-
parative effectiveness purposes based on direct and/or indirect
evidence. Even when results of the direct evidence are conclu-
sive, combining them with results of similar indirect estimates in
a mixed treatment comparison may yield a more precise esti-
mate for the interventions directly compared [4,5,12]. When we
use the term “network meta-analysis” in this report, we include
indirect treatment comparisons as well.
Despite the great realized and potential value of network
meta-analysis to inform health care decision making and its
increasing acceptance (e.g., Canadian Agency for Drugs and
Technologies in Health, National Institute for Health and Care
Excellence in the United Kingdom, Institute for Quality and
Efﬁciency in Health Care in Germany, and Haute Autorité de
Santé in France], it is not commonly used to inform health care
decisions, and many decision makers are not familiar with it.
There is a critical need for education on network meta-analysis,
as well as transparent and uniform ways to assess the quality of
reported network meta-analyses to help inform decision making.
In creating a questionnaire for health care decision makers to
assess network meta-analyses, the Task Force was asked to work
toward two goals. The ﬁrst was to provide a guide for gauging
one’s conﬁdence in the ﬁndings of a network meta-analysis. The
aim was to create a questionnaire for use by individuals with
understanding of principles of clinical research, but withoutin-depth knowledge of design and statistics. The second goal
was for the questionnaire to have educational and instructional
value to prospective users of network meta-analyses. We antici-
pate modiﬁcations to the structure, content, or wording of the
questionnaire based on the feedback, after it has been put to use.Questionnaire Development
One issue in creating questionnaires for decision makers is
whether they should be linked to scorecards, annotated score-
cards, or checklists. Concerns were raised by the Task Force that
a scorecard with an accompanying scoring system may be
misleading; it may not have adequate validity and measurement
properties. Scoring systems may also provide users with a false
sense of precision and have been shown to be problematic in the
interpretation of randomized trials [15].
An alternative to a scorecard is a checklist. However, it was
deemed by the Task Force that checklists might mislead users in
their assessments because a network meta-analysis may satisfy
all the elements of a checklist and still harbor “fatal ﬂaws” in the
methods applied in the publication. Moreover, users might have
the tendency to count up the number of elements present,
convert it into an implicit score, and then apply that implicit
scoring to their overall assessment of the evidence. In addition,
the applicability of a network meta-analysis may depend on
evidence external to the meta-analysis and speciﬁc to the setting
of interest. In general, a decision maker should be aware of the
strengths and weaknesses of each piece of information available
(one of which is a network meta-analysis) and apply his or her
own reasoning. Furthermore, a checklist format may undermine
the educational potential of the questionnaire.
The Task Force decided to develop a questionnaire charac-
terized by two principal concepts: relevance and credibility.
Relevance is the extent to which results of a network meta-
analysis, if trustworthy, apply to the setting of interest. The
relevance domain includes questions related to the population,
comparators, end points, time frame, and other policy-relevant
differences. Credibility is the extent to which the network meta-
analysis provides valid answers to the question it is designed to
answer. To generate questions for the credibility domain, the
Task Force relied on the expertise of its members and the
scientiﬁc literature including the reports of the ISPOR Task Force
and other pertinent publications on indirect treatment
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gested wording were also informed by earlier or recent efforts
that provided guidance to evidence reviewers [16,17]. Questions
guiding the assessment of credibility were grouped into ﬁve
subdomains: evidence base used for the indirect comparison or
network meta-analysis, analysis, reporting quality and trans-
parency, interpretation, and conﬂict of interest.
The developed questionnaire has 26 questions guiding the
reader in assessing the relevance (4 questions) and credibility (22
questions) of a network meta-analysis. Each question can be
answered with “Yes,” “No,” and “Can’t Answer.” “Can’t Answer”
can be used if the item is not reported in sufﬁcient detail or at all,
or if the assessor does not have sufﬁcient training to answer the
question. For one question (“Were statistical methods used that
preserve within-study randomization? (No naive comparisons)”),
a “No” will imply a fatal ﬂaw. This fatal ﬂaw suggests that
ﬁndings can be misleading and that the decision maker should
use caution in applying the ﬁndings to inform decisions. How-
ever, the occurrence of the fatal ﬂaw neither prevents a user from
completing the questionnaire nor does it mandate that such
results are deemed inappropriate for decision making.
On the basis of how questions are answered, the user would
make an overall judgment about each credibility subdomain. A
designation of “Strength” implies conﬁdence that the network
meta-analysis was conducted well and without inﬂuential short-
comings. A designation of “Neutral” suggests that potentially
important concerns are raised, but the user deemed them unlikely
to affect their credibility, as applicable. A designation of “Weakness”
suggests that the ﬁndings are likely to be biased and misleading
because of numerous or important shortcomings in the design or
conduct of the meta-analysis. Finally, a designation of “Fatal ﬂaw”
implies that the user believes that ﬁndings of the network meta-
analysis are likely to be biased and conclusions misleading.
Following on, the user will consider the domain judgments to
opine about the overall relevance and credibility of the network
meta-analysis for decision making, as either “sufﬁcient” or “insufﬁ-
cient.”Wewould like to remind that the questionnaire is not a score
or a checklist, in which one would count the frequency of each
designation to reach an overall judgment. We consider such
mechanistic approaches simplistic to say the least. The user will
judge whether and how to incorporate results from a network meta-
analysis in the decision-making process, after considering all inputs.
Following internal testing by the Task Force members during
September and October of 2012 and subsequent modiﬁcation of
the questionnaire, the revised questionnaire was further tested
by volunteers not involved in its development. Each volunteer
was asked to evaluate three published network meta-analysis
with the questionnaires being developed during April and May of
2013. Based on the feedback received, the current version of the
questionnaire was found helpful in assisting users systematically
opine about the relevance and credibility of network meta-
analysis studies to their setting of interest. The questionnaire is
provided in Appendix 1 in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2014.01.004.Questionnaire Items
This section provides detailed information to facilitate answering
the 26 questions. A glossary is provided in Appendix 2 in
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2014.01.004.
Relevance
Relevance addresses the extent to which the results of the network
meta-analysis apply to the setting of interest to the decisionmaker. A relative term, relevance has to be determined by each
decision maker and the respective judgment determined by one
decisionmaker will not necessarily apply to other decisionmakers.
1. Is the population relevant?
This question addresses whether the populations of the RCTs
that form the basis for the network meta-analysis sufﬁciently
match the population of interest to the decision maker (i.e., there
is no clinical reason to assume that the relative treatment effects
obtained with the network meta-analysis would not translate to
the population of interest to the decision maker). Relevant
population characteristics are not only limited to the speciﬁc
disease of interest but also pertinent to disease stage, severity,
comorbidities, treatment history, race, age, sex, and possibly
other demographic characteristics. Typically, RCTs included in
the network analysis are identiﬁed by means of a systematic
literature search with the relevant studies in terms of population
predeﬁned by study selection criteria. If these criteria are
reported, this is a good starting point to judge relevance in terms
of population. Evidence tables with inclusion criteria and base-
line patient characteristics for each study provide the most
relevant information to judge population relevance; exclusion
criteria are also noteworthy. For example, if a decision involves
covering a Medicare Part D population (e.g., those aged 65 years or
older), studies with few patients at or above 65 years of age may
be less relevant.
2. Are any relevant interventions missing?
This question gets at whether the intervention(s) included in the
network meta-analysis matches the one(s) of interest to the
decision maker and whether all relevant comparators have been
considered. Depending on the included RCTs, the network meta-
analysis may include additional interventions not necessarily of
interest for the decision maker. This does not, however, com-
promise relevance. Aspects to consider when judging the rele-
vance of included biopharmaceuticals are dose and schedule of a
drug, mode of administration, and background treatment. A
question whether the drug is used as induction or maintenance
treatment can be of relevance as well. For other medical tech-
nologies, one can consider whether the procedure or technique in
the trials is the same as the procedure or technique of interest to
the decision maker.
3. Are any relevant outcomes missing?
This question asks what outcomes are assessed in the network
meta-analysis and whether the outcomes are meaningful to the
decision maker. There has been increasing emphasis on out-
comes that are directly meaningful to the patient or the health
system such as cardiovascular events (e.g., myocardial infarction
and stroke) or patient functioning or health-related quality of life
(e.g., short-form 36 health survey and EuroQol ﬁve-dimensional
questionnaire) and decreasing emphasis on surrogate outcomes
(e.g., cholesterol levels) unless validated. Other considerations
include the feasibility of measuring relevant (i.e., ﬁnal) outcomes,
the predictive relationship between surrogate outcomes and ﬁnal
outcomes, and what kind of evidence will be considered “good-
enough,” given the patient population, the burden of the con-
dition, and the availability of alternative treatments (along with
the evidence supporting those treatments). Not only are the
outcomes themselves of interest, the timing of their assessment
is of interest as well. For example, a network meta-analysis that
included RCTs with a longer follow-up may be more relevant to
help inform treatment decisions for a chronic disease than a
network meta-analysis limited to studies with a short follow-up
(if follow-up is related to treatment effect).
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This question addresses whether there are any differences between
the RCTs included in the network meta-analysis versus the setting
and circumstances the decision maker is interested in. These
situations may not necessarily concern the population, interven-
tions, and outcomes but may still render the ﬁndings not appli-
cable. For example, the year when the studies included in the
network meta-analysis were performed can be of interest when
background medical care of a certain disease has dramatically
changed over time as when the standard treatment changes over
time. Many of the RCTs underlying network meta-analyses compar-
ing biopharmaceuticals are often designed for efﬁcacy (can it work?)
purposes and therefore the setting or circumstances may be differ-
ent from the real-world intent (does it work?). A relevant question
to ask, therefore, is whether the relative treatment effects and their
rank ordering of interventions as obtained with the network meta-
analysis would still hold if real-world compliance or adherence
would have been taken into consideration. The answer might be
“no” if some of the interventions are associated with a much lower
compliance in the real-world setting than other interventions.Credibility
Once the network meta-analysis is considered sufﬁciently rele-
vant, its credibility will be assessed. Credibility is deﬁned as the
extent to which the network meta-analysis or indirect compar-
ison accurately or validly answers the question it is designed to
answer. For the assessment questionnaire, we take the position
that credibility is not limited to internal validity (i.e., the
observed treatment effects resulting from the analysis reﬂectFig. 1 – Overview of domains related to assessment of the credi
randomized controlled trials; RE, random effects.the true treatment effects) but also concerns reporting quality
and transparency, interpretation, and conﬂict of interest (see
Fig. 1). The internal validity of the network meta-analysis can be
compromised as a result of the presence of bias in the identi-
ﬁcation and selection of studies, bias in the individual studies
included, and bias introduced by the use of inappropriate
statistical methods.
Evidence Base Used for the Indirect Comparison or Network
Meta-Analysis
The ﬁrst six questions of the credibility domain pertain to the
validity of the evidence base feeding information into the net-
work meta-analysis.
1. Did the researchers attempt to identify and include all
relevant RCTs?
To have a network meta-analysis that reﬂects the available
evidence base, a systematic literature search needs to be per-
formed. Although there is no guarantee that all relevant studies
can be identiﬁed with the search, it is important that the
researchers at least attempt to achieve this goal. Important
things to consider include the following:biliDid the search strategy target RCTs between all interventions of
interest? Were multiple databases searched (e.g., MEDLINE, EMBASE, and
Cochrane Central Registry of Trials)? Would review selection criteria admit all RCTs of interest (if
identiﬁed by the literature search)?ty of a network meta-analysis. FE, ﬁxed effects; RCTs,
Fig. 2 – Connected networks of randomized controlled trials
to allow for network meta-analysis and indirect
comparisons. All interventions that can be indirectly
compared are part of one network.
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clude all available relevant published RCTs (of course one would have
to review the syntax of the actual search strategies to authoritatively
discuss their adequacy). An additional step to identify missing or
unpublished key studies would be to search clinical trial databases,
such as http://dx.doi.org/clinicaltrials.gov. Systematic reviews that
follow the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses reporting guidelines are easier to assess [18].
2. Do the trials for the interventions of interest form one
connected network of RCTs?
To allow comparisons of treatment effects across all interven-
tions in the network meta-analysis, the evidence base used for
the meta-analysis should correspond to a connected network. In
simple terms, this means that any two treatments can be
compared either directly (head to head) or indirectly, through
(one or more) intermediate common referents. Figure 2 depictsFig. 3 – Treatment effects, study effects, effect modiﬁers, and pfour connected evidence networks. The nodes represent inter-
ventions, and the edges (i.e., connections) imply that one or more
RCTs have compared the respective treatments directly. Any two
treatments that have not been compared head to head are
amenable to an indirect comparison. For example, the network
in Figure 2A includes AB studies comparing intervention B with A
and AC studies comparing intervention C with A. The relative
treatment effect of C versus B can be obtained with the indirect
comparison of the AB and AC studies. The network in Figure 2B
also includes CD studies, and can inform on any pairwise
comparison (i.e., contrasts) among A, B, C, and D. The networks
in Figure 2C,D have a closed loop, which implies that for some of
the treatment comparisons there is both direct and indirect
evidence. In Figure 2C, there is both direct and indirect evidence
for the AB, AC, and BC comparisons. In Figure 2D, there is direct
and indirect evidence for all comparisons with the exception of
the AD and BC contrast, for which there is only indirect evidence.
In RCTs, the observed outcome with an intervention is the result
of study characteristics, patient characteristics, and the treatment
itself. In a placebo-controlled trial, the result of the placebo arm
reﬂects the effect of study and patient characteristics on the
outcome of interest, say, outcome y (see Fig. 3). In other words,
the placebo response is the result of all known and unknown
prognostic factors other than active treatment. We can call this the
study effect. In the active intervention arm of the trial, the observed
outcome y is a consequence of the study effect and a treatment
effect. By randomly allocating patients to the intervention and
placebo groups, both known and unknown prognostic factors (as
well as both measured and unmeasured prognostic factors)
between the different groups within a trial are on average balanced.
Hence, the study effect as observed in the placebo intervention arm
is expected to be the same in the active intervention arm and,
therefore, the difference between the active intervention arm and
the placebo intervention arm (say delta y) is attributable to the
active intervention itself, resulting in a treatment effect.
With an indirect comparison, interest centers on the compar-
ison of the treatment effects of interventions that are not studied
in a head-to-head fashion. To ensure that the indirect compar-
isons of interventions are not affected by differences in study
effects between studies, we want to only consider the treatment
effects of each trial. This consideration implies that all interven-
tions indirectly compared have to be part of one network of trials
in which each trial has at least one intervention (such as placebo)
in common with another trial, as illustrated in Figure 4. If some
interventions of interest are not part of the same network, then itrognostic factors in a randomized placebo-controlled trial.
Fig. 4 – Indirect comparison of AB, AC, and CD studies in which each trial is part of one network. y refers to the outcome of
interest on a continuous scale, for example, change from baseline in pain, or log odds of a response; delta y vs. A reﬂects the
difference in the outcome of interest with treatment B, C, and D relative to treatment A. Note. In terms of treatment effects, B is
more efﬁcacious than A, C is more efﬁcacious than B, and D is more efﬁcacious than C. Tx, treatment.
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effects of these interventions without a substantial risk of bias, as
illustrated in Figure 5.
3. Is it apparent that poor quality studies were included, thereby
leading to bias?
The validity of the network meta-analysis is at risk not only when
certain studies are not identiﬁed but also when the internal
validity of individual RCTs is compromised. To answer this
credibility question, the network meta-analysis report should have
provided summary information on key study characteristics of
each RCT, such as method of randomization, treatment allocation
concealment, blinding of the outcome assessor, and dropout.
Frequently, a network meta-analysis report provides an overview
of bias in individual studies as assessed with a speciﬁc checklist
for individual study validity, such as the Cochrane Collaboration’s
tool for assessing risk of bias in randomized trials [19].
4. Is it likely that bias was induced by selective reporting of
outcomes in the studies?
Outcome reporting bias occurs when outcomes of the individual
trials are selected for publication on the basis of their ﬁndings
[20]. This can result in biased treatment effect estimates obtainedwith the network meta-analysis. As an assessment of the like-
lihood of bias due to selective reporting of outcomes, a determi-
nation can be made whether there is consistency in the studies
used for the network meta-analysis with respect to the different
outcomes. In other words, a check should be placed whether any
of the selected studies do not report some of the outcomes of
interest and were therefore not included in some of the network
meta-analyses of the different end points. It can be informative
to look at the original publication of the suspect study whether
there is any additional information. Furthermore, if reported in
the network meta-analysis report, a check on the reasons studies
were excluded from the systematic review would be beneﬁcial to
ensure no eligible studies were excluded only because the out-
come of interest was not reported [20]. If this were the case, a
related risk of bias—publication bias—in the overall ﬁndings of
the network meta-analysis would manifest itself.5. Are there systematic differences in treatment effect modiﬁers
(i.e., baseline patient or study characteristics that have an
impact on the treatment effects) across the different treatment
comparisons in the network?
Study and patient characteristics can have an effect on the
observed outcomes in the intervention and control arms of an
Fig. 5 – AB and CD studies that do not have an intervention in common, making an indirect comparison without a substantial
risk of bias not feasible. Tx, treatment.
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that affect outcome to the same extent in the active interven-
tion and placebo intervention arms are called prognostic factors.
More speciﬁcally, the placebo response, which serves as a baro-
meter of study effect, captures the effect of all study and patient
characteristics that are prognostic factors on the outcome of
interest.
Study and patient characteristics that affect the difference
between the active intervention and the placebo intervention
regarding the outcome of interest are treatment effect modiﬁers
(Fig. 3). For example, if a medical intervention works only for men
and not for women, a trial among men will demonstrate a
positive treatment effect relative to placebo, whereas a trial only
among women would not. Sex is a treatment effect modiﬁer for
that intervention. As another example, if the outcome of interest
(e.g., improvement in pain) is greater in a 24-week trial than in a
12-week trial, and there is no difference in the treatment effect of
the intervention relative to placebo between the 24-week trial
and the 12-week trial, then trial duration is only a prognostic
factor and not an effect modiﬁer. If a variable is both a prognostic
factor of the outcome of interest and a treatment effect modiﬁer,
then the placebo response (or baseline risk) of a placebo-
controlled trial is associated with the treatment effect.
Although the indirect comparison or network meta-analysis is
based on RCTs, randomization does not hold across the set of
trials used for the analysis because patients are not randomizedto different trials. As a result, systematic differences in the
distribution of patient characteristics across trials can ensue. In
general, if there is an imbalance in study and patient character-
istic–related effect modiﬁers across the different types of direct
comparisons in a network meta-analysis, the corresponding
indirect comparisons are biased [21,22]. In Figures 6 to 8, exam-
ples of valid and biased indirect comparisons from a network
meta-analysis are provided. It is important to acknowledge that
there is always some risk of imbalances in unknown or unmeas-
ured effect modiﬁers between studies evaluating different inter-
ventions. Accordingly, there is always a small risk of residual
confounding bias, even if all observed effect modiﬁers are bal-
anced across the direct comparisons.
The answer to question 5 is a “yes” if there are substantial (or
systematic) differences in effect modiﬁers, which can be judged
by comparing study-speciﬁc inclusion and exclusion criteria,
baseline patient characteristics, and study characteristics that
are expected to be effect modiﬁers.
6. If yes (i.e., there are such systematic differences in treatment
effect modiﬁers), were these imbalances in effect modiﬁers
across the different treatment comparisons identiﬁed before
comparing individual study results?
Frequently, there are several trial and patient characteristics that
are different across the different direct comparisons. Deciding
Fig. 6 – Indirect comparison of an AB and AC study with different proportions of patients with moderate and severe disease.
Note. Disease severity is an effect modiﬁer. The indirect comparison for the moderate disease subgroup is valid, as is the
indirect comparison for the severe subgroup. The indirect comparison of the results for the overall population of both studies
is biased because the distribution of the effect modiﬁer severity is different for the AB and AC studies.
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in the results across trials can lead to false conclusions regarding
the sources of inconsistency and biased indirect comparisons
[22,23]. It is recommended that researchers undertaking the
network meta-analysis ﬁrst generate a list of potential treatment
effect modiﬁers for the interventions of interest on the basis of
previous knowledge or reported subgroup results within individ-
ual studies before comparing results between studies. Next, the
study and patient characteristics that are determined to be likely
effect modiﬁers should be compared across studies to identify
any imbalances between the different types of direct compar-
isons in the network.Analysis
The next seven questions pertain to the statistical methods used
for the network meta-analysis.
7. Were statistical methods used that preserve within-study
randomization? (No naive comparisons)
To acknowledge the randomization of treatment allocation within
RCTs and thereby minimize the risk of bias as much as possible, a
network meta-analysis of RCTs should be based on their relative
treatment effects [4–14]. In other words, statistical methods need to
be used that preserve within-study randomization. An invalid or
Fig. 7 – Valid network meta-analysis of AB and AC studies with and without heterogeneity: No imbalance in the distribution of
the effect modiﬁer disease severity between AB and AC comparisons.
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ization is presented in Figure 9. The naive indirect comparison does
not take any differences in study effects (as represented with the
white boxes representing placebo) across trials into account. With
RCTs available that are part of one evidence network, the naive
indirect comparison can be considered a fatal ﬂaw.Fig. 8 – Biased network meta-analysis of AB and AC studies with
the effect modiﬁer disease severity between AB and AC compar8. If both direct and indirect comparisons are available for
pairwise contrasts (i.e., closed loops), was agreement in
treatment effects (i.e., consistency) evaluated or discussed?
If a network has a closed loop, there is both direct evidence and
indirect evidence for some treatment contrasts (Fig. 10). Forand without heterogeneity: Imbalance in the distribution of
isons.
Fig. 9 – Naive indirect comparison that is invalid because
differences in study effects are not acknowledged. Note. In
this example, the difference in the treatment effect of C
versus B is overestimated. Tx, treatment.
Fig. 10 – Example of a closed loop network that exhibits co
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and BC trials, direct evidence for the BC contrast is provided by
the BC trials and indirect evidence for the BC contrast is provided
by the indirect comparison of AC and AB trials. If there are no
systematic differences in treatment effect modiﬁers across the
different direct comparisons that form the loop, then there will be
no systematic differences in the direct and indirect estimate for
each of the contrasts that are part of the loop [4,10,22]. Combining
direct estimates with indirect estimates is valid, and the pooled
(i.e., mixed) result will reﬂect a greater evidence base and one
with increased precision regarding relative treatment effects.
However, if there are systematic differences in effect modiﬁers
across the different direct comparisons of the network loop, the
direct estimates will be different from the corresponding indirect
estimates and combining these may be inappropriate (Fig. 11).
Hence, it is important that in the presence of a closed loop any
direct comparisons are compared with the corresponding indirect
comparisons regarding effects size or distribution of treatment
effect modiﬁers. However, statistical tests for inconsistency
should not be overinterpreted and should include knowledge of
the clinical area.nsistency between direct and indirect comparisons.
Fig. 11 – Example of a closed loop network that exhibits inconsistency between direct and indirect comparisons.
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comparisons, were both direct and indirect evidence included in
the network meta-analysis?
If there is a closed loop in an evidence network, the relative
treatment effect estimates obtained with direct comparisons are
comparable to those obtained with the corresponding indirect
comparisons, and there is no (substantial) imbalance in the
distribution of the effect modiﬁers, then it is of interest to combine
results of direct and indirect comparisons of the same treatment
contrast in a network meta-analysis. As a result, the pooled result
will be based on a greater evidence base with increased precision
for relative treatment effects than when only direct evidence for
the comparison of interest would be considered [4,5,10,12].
10. With inconsistency or an imbalance in the distribution of
treatment effect modiﬁers across the different types of
comparisons in the network of trials, did the researchers
attempt to minimize this bias with the analysis?
In general, if there is an imbalance in the distribution of effect
modiﬁers across the different types of direct comparisons,
transitivity (e.g., if C is more efﬁcacious than B, and B moreefﬁcacious than A, then C is more efﬁcacious than A) does not
hold and the corresponding indirect comparison is biased and/or
there is inconsistency between direct and indirect evidence
(Figs 8 and 11).
If there are a sufﬁcient number of studies included in the
network meta-analysis, it may be possible to perform a meta-
regression analysis in which the relative treatment effect of each
study is a function of not only a treatment comparison of that
study but also an effect modiﬁer [23–27]. In other words, with a
meta-regression model we estimate the pooled relative treat-
ment effect for a certain comparison on the basis of available
studies, adjusted for differences in the level of the effect modiﬁer
between studies. This will allow indirect comparisons of different
treatments for the same level of the covariate, assuming that the
estimated relationship between effect modiﬁer and treatment
effect is not greatly affected by ecological bias (see Fig. 12) with a
relationship at the aggregated study level not necessarily equat-
ing to the true relationship found in the individual patient data.
For example, if there are differences in the proportion of subjects
with severe disease among trials and disease severity affects the
efﬁcacy of at least one of the compared interventions, a meta-
regression analysis can be used to adjust the indirect comparison
Fig. 12 – Network meta-analysis without and with adjustment for imbalance in effect modiﬁer using a meta-regression model.
Note. With this approach, the treatment effects for AC and AB depend on the value of the effect modiﬁer.
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In addition, the model can predict indirect treatment comparison
estimates for different proportions of patients with severe dis-
ease in a population.
A challenge with meta-regression analysis is the low power
that depends on the number of studies. Having access to patient-
level data for a subset of the evidence base improves parameter
estimation of meta-regression network meta-analysis models
[28–30]. With these models, it is important to understand that
we aim to explain the effect of modiﬁers of the relative treatment
effects; given the network, there is no need to adjust for differ-
ences in the study effects (or prognostic factors in general)
between RCTs. That being said, one can use the placebo response
of a study as the covariate to adjust for any inconsistency, but
this relies on the assumption that study and patient character-
istics (such as severity of illness) that are effect modiﬁers of the
relative treatment effect are also prognostic factors of the out-
come with placebo [22]. However, this assumption is not trivial to
examine and requires appropriate model speciﬁcation.
As an alternative to a meta-regression analysis, researchers
can also attempt to use models with so-called inconsistency
factors [31,32]. These network meta-analysis models explicitly
acknowledge any difference between direct and indirect relative
treatment effect estimates of two interventions and thereby
are less prone to bias estimates when direct and indirect
estimates are pooled. However, the interpretation of thetreatment effects obtained with these models is not useful for
decision making.
In the absence of inconsistency and absence of differences in
effect modiﬁers between different types of direct comparisons,
this question should be answered with a “yes”. If there are
inconsistencies or systematic differences in effect modiﬁers across
comparisons, this question will also be answered with “yes” if
meta-regression models that are expected to explain or adjust for
the consistency or bias were used. (Yes, the researchers attempted
to minimize the bias with this analysis). Of course, one needs to be
aware of the risk of model misspeciﬁcation, instable estimates,
and ecological bias when using only study-level data. In the
presence of inconsistency, but the researchers did not attempt to
adjust for this, the question should be answered with “no.”11. Was a valid rationale provided for the use of random-effects
or ﬁxed-effect models?
Most, if not all, meta-analyses include studies that are clinically
and methodologically diverse, and thus one expects that
between-study heterogeneity in treatment effects will be present.
Thus, we generally advocate using a random-effects model to
combine data [33]. A random-effects model assumes that each
study has its own true treatment effect, because study character-
istics and the distribution of patient-related effect modiﬁers
differ across studies. The study-speciﬁc true effects are then
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meta-analysis mean), and with a variance (between-study heter-
ogeneity) that reﬂects how different the true treatment effects
are between them. Especially for the network meta-analysis case,
several random-effect model variants have been proposed. In
contrast, a ﬁxed-effect (equal-effect) model assumes that the true
treatment effect is common in all studies comparing the same
treatments. This implies that there are no effect modiﬁers, or
that they have the same distribution across all studies in the
meta-analysis. The plausibility of model assumptions should
guide model choice, and, in general, we deem that the assump-
tions of random-effects models are much more plausible than of
ﬁxed-effect models.
Often, model ﬁt criteria are invoked for choosing between
models, where the model with the better trade-off between ﬁt and
parsimony (the ﬁxed-effect model being the most parsimonious)
is preferred. However, model ﬁt is not a proxy for the plausibility
of model assumptions. Model ﬁt criteria have a role in choosing
between variants of random-effects models, but even in these
cases they represent an operationalization. Solely relying on a
statistical test for homogeneity to argue the use of the ﬁxed-effect
model instead of the random-effects model cannot be considered
sufﬁcient, either.
An argument for the use of a ﬁxed-effect model instead of a
random-effects model should include a judgment about the
similarity of studies according to important effect modiﬁers and
the prior belief, based on experience with the relevant clinical
ﬁeld, that the intervention is likely to have a ﬁxed relative effect
irrespective of the populations studied.
If it is technically not feasible to estimate the heterogeneity
parameter of a random-effects model, which is, for example, the
case in a star-shaped evidence network with only one study for
each direct comparison, one may have used a ﬁxed-effect model.
However, it is important that the effect of ignoring heterogeneity
on the ﬁndings is acknowledged. In such a situation, it is arguably
still preferable to use a random-effects model and make assump-
tions about the extent of heterogeneity (i.e., assuming a value for
the heterogeneity parameter).12. If a random-effects model was used, were assumptions
about heterogeneity explored or discussed?
With random-effects models, the between-study variation in
treatment effects for the direct comparisons is explicitly taken
into consideration. In a network meta-analysis, variants of the
random-effects model exist. Two common variants differ in their
assumptions about between-study heterogeneity for each com-
parison among treatments. One assumes that between-study
heterogeneity is the same for all comparisons, and another
allows between-study heterogeneity to differ by comparison.
Exploration or, at least, a discussion of the choice between
random-effects variants is desirable.
This question is not applicable if the network meta-analysis
used a ﬁxed-effect model.13. If there are indications of heterogeneity, were subgroup
analyses or meta-regression analysis with prespeciﬁed
covariates performed?
Heterogeneity in relative treatment effects (i.e., true variation in
relative treatment effects across studies comparing the same
interventions) can be captured with random-effects models, but
the analysis will provide the average relative treatment effect
across the different levels of the responsible effect modiﬁer(s).
This ﬁnding may not be very informative for decision making,
especially if there are great differences in relative treatment
effects for the different levels of the effect modiﬁers [33]. It ismore informative to estimate relative treatment effects for the
different levels of the effect modiﬁer, either with subgroup
analysis or with a meta-regression analyses in which treatment
effects are modeled as a function of the covariate, as illustrated in
Figure 12.
Often there are a limited number of trials in a network
meta-analysis, but many trial and patient characteristics may
be different across studies. Deciding which covariates to include
in the meta-regression models used for the network meta-
analysis based on observed patterns in the data of the trials
can lead to false conclusions regarding the sources of hetero-
geneity [23,24]. To avoid data dredging, it is strongly recom-
mended to prespecify the potential treatment effect modiﬁers
that will be investigated.
This question is not applicable if the network meta-analysis
used a ﬁxed-effect model or if there was no indication of
between-study heterogeneity.
Reporting Quality and Transparency
The next six questions pertain to the transparency in the
presentation of the evidence base and the results of the network
meta-analysis. With a sufﬁciently transparent presentation, the
credibility of the ﬁndings given the available studies can be
accurately assessed and, if desired, replicated.
14. Is a graphical or tabular representation of the evidence
network provided with information on the number of RCTs per
direct comparison
To help understand the ﬁndings of a network meta-analysis, an
overview of the included RCTs is required. The evidence base can
be summarized with an evidence network in which the available
direct comparisons are reﬂected with edges (i.e., connections)
between the different interventions along with the number of
RCTs per direct comparison. It is recommended that any trial that
compares more than two interventions (i.e., more than two arms)
is highlighted. With such a network, it is immediately clear for
which treatment contrasts there is direct evidence, indirect
evidence, or both [34]. A table in which studies are presented in
the rows, the interventions in the columns, and observed results
with each intervention of each study in the cells can prove
informative as well.
15. Are the individual study results reported?
To assess the (face) validity of the results of the network meta-
analysis, the individual study results need to be provided,
either in the publication or in an online supplement. More
speciﬁcally, presentation of the individual study results allows
reviewers to compare these with the results of the network
meta-analysis. It will also facilitate replication of the analysis,
if desired.
16. Are results of direct comparisons reported separately from
results of the indirect comparisons or network meta-analysis?
To judge whether the assumption of consistency between direct
and indirect evidence holds, estimates of (pooled) direct compar-
isons can be compared with estimates obtained from the corre-
sponding indirect comparisons [32]. However, this is not a trivial
task. A more pragmatic approach is to present (pooled) direct
evidence separately from results of the network meta-analysis in
which direct and indirect evidence for some comparisons (i.e.,
presence of closed loops) are combined. Although the absence of
a difference between these two sets of results does not guarantee
there is no inconsistency, the opposite does hold: If the results
based on direct evidence are systematically different from results
based on the combination of direct and indirect evidence, then
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evidence.17. Are all pairwise contrasts between interventions as obtained
with the network meta-analysis reported along with measures
of uncertainty?
With a network meta-analysis, relative treatment effect esti-
mates between all the interventions included in the analysis
can be obtained. For decision making it is very informative when
all these possible contrasts are presented. Equally important, for
every relative treatment effect that is estimated, measures of
uncertainty need to be presented (i.e., 95% conﬁdence intervals
(CI) or 95% credible intervals (CrI), which will be deﬁned in the
next section).18. Is a ranking of interventions provided given the reported
treatment effects and its uncertainty by outcome?
A network meta-analysis can be performed in a frequentist or a
Bayesian framework. The result of a frequentist network meta-
analysis comparing treatments is an estimate of the relative
treatment effect along with a P value and 95% CI. The P value
indicates whether the results are statistically “signiﬁcant” or
“nonsigniﬁcant.” The P value reﬂects the probability of having a
test statistic at least as extreme as the one that was actually
observed assuming that the null hypotheses (e.g., no difference
between treatments) are true [35]. The usefulness of the P value,
though, is limited for decision making because it does not provide
information on the probability that a hypothesis (e.g., one treat-
ment is better than the other) is true or false. Moreover, when the
decision maker is faced with a choice between more than two
treatments, the interpretation of a P value associated with each
pairwise comparison in a network meta-analysis becomes even
more difﬁcult because it does not provide information about the
ranking of treatments. The 95% CIs corresponding to the effect
estimate as obtained within a frequentist framework cannot be
interpreted in terms of probabilities either; the 95% CI does not
mean that there is a 95% probability that the true value is
between the boundaries of the interval.
Within the Bayesian framework, the belief regarding the
treatment effect size before looking at data can be conveyed with
a probability distribution: the prior distribution. This probability
distribution will be updated after having observed the data,
resulting in the posterior distribution summarizing the updated
belief regarding the likely values for this effect size [36]. The
output of the Bayesian network meta-analysis is a joint posterior
distribution of all relative treatment effects between interven-
tions included in the network. The posterior distribution for each
relative treatment effect can be summarized with a mean or
median to reﬂect the most likely value for the effect size, as well
as the 2.5th and 97.5th percentile: the 95% CrI. In Figure 13, the
output obtained with a frequentist and Bayesian network meta-
analysis is summarized. In the frequentist framework, we obtain
relative treatment effects of each intervention relative to a
control, along with a 95% CI (and P value). In the Bayesian
framework, however, we obtain posterior probability distribu-
tions summarizing the likely values for the treatment effect of
each intervention relative to a control, which are typically
reported as a “point estimate” and a 95% CrI.
Because the posterior distribution is a probability distribution,
it allows for probability statements. Unlike the 95% CI obtained
with the frequentist framework, the 95% CrI can be interpreted in
terms of probabilities: there is a 95% chance that the true effect
size falls between the boundaries of the CrI. Consequently, in a
network meta-analysis ﬁtted within a Bayesian framework, the
multiple inferences based on CIs or P values can be replaced withprobability statements (see Fig. 14). For example, “ there is x%
probability that treatment C is better than B,” or “there is a y%
probability that treatment D is the most efﬁcacious out of treat-
ment A, B, C, D, and E regarding this outcome,” or “there is z%
probability that intervention E is the least efﬁcacious” [37].
For each outcome of interest, the probability that each treat-
ment ranks ﬁrst, second, third, and so on out of all interventions
compared can be called rank probabilities and are based on the
location, spread, and overlap of the posterior distributions of the
relative treatment effects. Rank probabilities can be summarized
with a graph in which on the horizontal axis the rank from 1 to
the number of treatments in the analysis is provided, and the
vertical axis reﬂects a probability. Now, for each treatment the
probability against the rank is plotted and these dots connected
by treatment: a rankogram as illustrated in Figure 15 [37].
Alternatively, the ranking probabilities can be presented with
bar charts. Note that solely presenting the probability of being the
best can result in erroneous conclusions regarding the relative
ranking of treatments because interventions for which there is a
lot of uncertainty (i.e., wide CrI) are more likely to be ranked best.
The beneﬁt of having rank probabilities is that these “summa-
rize” the distribution of effects, thereby acknowledging both
location and uncertainty. Alternative summary measures of rank
probabilities, such as the surface under the cumulative ranking
curve, have also been proposed [37].
Technically, one can approximate the results of a Bayesian
analysis that has uninformative priors using the numerical results
from a model ﬁt with maximum likelihood in a frequentist setting.
This slight of hand corresponds to interpreting the likelihood
function as a probability distribution and implies a Bayesian
interpretation of a frequentist analysis. Thus, one could “obtain”
approximations of rank probabilities even from a network meta-
analysis performed in a frequentist framework, assuming non-
informative priors.
19. Is the effect of important patient characteristics on treatment
effects reported?
If it has been determined that certain patient characteristics are
effect modiﬁers and differ across studies, then it is of interest to
report relative treatment effects for different levels of the effect
modiﬁer as obtained with meta-regression analysis or subgroup
analyses. Factors of interest can include sex, severity of disease,
distribution of biomarkers, and treatment history, for example.
Interpretation
20. Are the conclusions fair and balanced?
If the conclusions are in line with reported results of the network
meta-analysis, the available evidence base, credibility of the
analysis methods, and any concerns of bias, then the conclusions
can be considered to be fair and balanced.
Conﬂict of Interest
21. Were there any potential conﬂicts of interest?
Conﬂicts of interest may exist when an author (or author’s
institution or employer) has ﬁnancial or personal relationships
or afﬁliations that could affect (or bias) the author’s decisions,
work, or manuscript.
22. If yes, were steps taken to address these?
To address potential conﬂicts of interest, all aspects of conﬂicts of
interest should be noted (including the speciﬁc type and relation-
ship of the conﬂict of interest), and the publication should be peer
reviewed. The contribution of each author should be clearly
noted to document full disclosure of activities. Also, a fair and
Fig. 13 – Frequentist versus Bayesian output of a network meta-analysis.
Fig. 14 – Probabilistic interpretation of posterior distribution
with Bayesian framework.
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study’s limitations, should be accurately discussed.Discussion
The objective of this study was to develop a questionnaire to help
evidence evaluators form their opinions on the relevance and
credibility of a network meta-analysis to help inform health care
decision making. Relevance has to do with the extent to which
the network meta-analysis is applicable to the problem faced by
the decision maker. Credibility has to do with the extent to which
the ﬁndings of the network meta-analysis are valid and trust-
worthy. The questionnaire also has an educational purpose: to
raise awareness that evidence evaluation can be challenging and
important elements may not be obvious to all potential users.
Furthermore, the questionnaire may provide guidance to
researchers when performing a network meta-analysis.
The developed questionnaire, building upon earlier work
[13,16,17], assists evidence evaluators in applying a structured
and consistent approach. The questionnaire does not determine
an overall impression or summary score. Although some may be
interested in such scores to facilitate overall evidence synthesis,
the use of such scores can be misleading. In addition, the
applicability of a study may depend on whether there is any
other evidence that addresses the speciﬁc issue or the decision
Fig. 15 – “Rankograms” showing the probability for each treatment to be at a speciﬁc rank in the treatment hierarchy.
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of the strengths and weaknesses of each piece of evidence and
apply his or her own reasoning.
Our questionnaire is reminiscent of the Grading of Recommen-
dations, Assessment, Development and Evaluation (GRADE) Work-
ing Group framework for systematic reviews or for clinical practice
guidelines but has important differences [38]. The GRADE system
aims to characterize the likelihood that a clinically important
causal effect exists primarily when two treatments are compared.
GRADE evaluates ﬁve dimensions that it calls “directness,” “con-
sistency,” “precision,” “risk of bias,” and “miscellaneous issues.”
“Directness” in GRADE is similar to our relevance domain, and “risk
of bias” is subsumed by our credibility domain. In GRADE, “pre-
cision” is related to the decision maker’s conﬁdence that a clinically
important true effect exists and “consistency” refers to the con-
gruence of the various sources of evidence that are being consid-
ered by the decision maker. However, a formal decision-making
process (e.g., a decision analysis) subsumes the assessments of
“precision” and “consistency” by calculating expectations for the
decision-relevant quantities and by propagating uncertainty. Thus,
we deemed that the appropriate scope for the questionnaire is to
include only the relevance and credibility domains.User Testing
The Task Force wanted to strike a balance between simplicity and
comprehensiveness to ensure a questionnaire useful for the end
user who is not necessarily a methodologist. Approximately 22
persons, with different levels of epidemiological, statistical, and
clinical expertise, were solicited to participate in user testing.
Each volunteer was asked to evaluate three published network
meta-analysis, rated by the Task Force as “good quality,”
“medium quality,” and “poor quality,” respectively. The response
was 82%. There were not enough users to perform a formal
psychometric evaluation of the questionnaire. However, some
insightful and interesting descriptive observations could be made.We calculated multirater agreement (calculated as the percent-
age agreement over the response categories “yes,” “no,” “not
applicable,” “not reported,” and “insufﬁcient information” for each
credibility question) as an indirect indication of the clarity of the
phrasing of the credibility domain (people can legitimately disagree
in their assessments/interpretations). Agreement exceeded 80% for
8 of the 22 questions. The average agreement score was 72%, with a
range of 42% to 91%. As expected, the lowest agreement scores
were observed for the credibility questions 5, 6, 10, 13, and 19
relating to the key concepts “effect modiﬁers,” “inconsistency,” and
“heterogeneity.” Agreement in responses was greater for the study
the Task Force selected as a good example. Agreement about the
overall credibility was 83%. The good-quality study was generally
rated as sufﬁcient with respect to relevance and credibility, while
the poor-quality study was generally rated not sufﬁcient.
These descriptive results are congruent with the Task Force’s a
priori expectations, and thus the current version of the question-
naire was deemed acceptable for wider release. Over time,
we expect to change the content or phrasing of the questionn-
aire, based on feedback from users. In practice, the questionnaire
does not have to be completed by a single individual. Completion
by a cross-disciplinary team consisting of a clinician and a
statistician can be very useful. The clinician can answer questions
related to interventions, outcomes, and effect modiﬁers, whereas
the statistician can answer questions related to analytical issues.Educational Needs
Across many international jurisdictions, the resources and expertise
available to inform health care decision makers vary widely.
Although there is broad experience in evaluating evidence from
RCTs, there is less experience with network meta-analysis among
decision makers. ISPOR has provided Good Research Practice rec-
ommendations on network meta-analysis [14,15]. This questionnaire
is an extension of those recommendations and serves as a platform
to assist the decision maker in understanding what a systematic
evaluation of this research requires. By understanding what a
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analysis entails, it is hoped that this will lead to a general increase in
sophistication by decisionmakers in the use of this evidence. To that
end, we anticipate additional educational efforts and promotion of
this questionnaire and that it will be made available to an increasing
number of health care decision makers. In addition, an interactive
(i.e., web-based) questionnaire has been developed at https://www.
healthstudyassessment.org/ that will facilitate uptake and support
the educational goal of the questionnaire.Conclusions
The Task Force developed a consensus-based questionnaire to
help decision makers assess the relevance and credibility of
meta-analysis to help inform health care decision making. The
questionnaire aims to provide a guide for assessing the degree of
conﬁdence that should be placed in a network meta-analysis, and
enables decision makers to gain awareness of the subtleties
involved in evaluating these kinds of studies. It is anticipated
that user feedback will permit periodic evaluation and modiﬁca-
tion to the questionnaires, with the ensuing improvement to it.
The goal is to make these questionnaires as useful as possible to
the health care decision-making community.
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